Singapore, Jan. 12 -- SK bioscience has announced the new domestic launch of MenQuadfi Injection (MenQuadfi, MenACWY-TT), a quadrivalent meningococcal conjugate vaccine, in partnership with the Korean affiliate of global biopharmaceutical company Sanofi.

Developed by Sanofi, MenQuadfi is approved for use in individuals from 6 weeks of age through 55 years and is indicated for the prevention of Invasive Meningococcal Disease (IMD) caused by the major meningococcal serogroups A, C, W, and Y.

Published by HT Digital Content Services with permission from BioSpectrum Asia....